slowed brain tumor growth in a preclinical model and extended survival
more than 10-times the rate of the current standard-of-care chemotherapy drug.
in human glioblastoma cells that
ibrutinib works by inhibiting glioma stem cells—an aggressive type of brain
cancer cell that tends to resist treatment and spread. Furthermore, dr showed that combining ibrutinib with radiation
therapy prevents glioblastoma cells from developing this resistance.
Combination therapy overcame resistance and extended lifespan more effectively
than either radiation or ibrutinib treatment alone.
According to the Dr's are said glioblastoma
survival is very poor—median survival in patients undergoing standard treatment
is less than 15 months. Glioblastoma is
the most lethal primary brain tumor and is highly resistant to
current therapies," There is an urgent need to get new treatments to these
patients as quickly as possible."
In
earlier studies, Dr's are found that glioma stem cells have high levels of a
protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX
activates a protein called STAT3 (signal transducer and activator of
transcription 3), which is responsible for the aggressive, pro-cancer qualities
of glioma stem cells. In this new study, the researchers found that ibrutinib
works by inhibiting both proteins.
"Additional
research is important to understand the effects of ibrutinib in patients, but
these early findings are promising," "Using an FDA-approved drug
would allow us to surpass many of the lengthy regulatory studies needed when
developing a new treatment, and we could potentially begin clinical trials very
soon."
Ibrutinib
(Imbruvica) has been approved by the U.S. Food & Drug Administration to
treat certain types of leukemia and lymphoma, as well as chronic graft versus
host disease.
For more details regarding conference:https://neurooncology.conferenceseries.com/conference-brochure.php
Kindly contact the below e-mail id : neurooncology@conferenceint.com
No comments:
Post a Comment